Equine Clinical Data & Technical Information

Equine clinical study under construction

Additional Clinical Data

The Effect of Collagen-Elastin Hydrogel Microparticles (CEHM) on Pain and Function Secondary to Hip Osteoarthritis in Dogs

Amalfitano A, Gaynor JS, Stewart SD. 2024 VOS Annual Conference, Lake Tahoe, CA, February 10-17, 2024.


A Collagen-Elastin Hydrogel Microparticulate (CEHM), commercially known as Spryng, was evaluated as a potential or hip osteoarthritis (OA) in dogs. A Simon's 2-stage design was used to assess safety and efficacy. Fourteen dogs with radiographic evidence of hip OA were enrolled. CEHM was injected into the affected hip(s) under general anesthesia. Assessments included physical examination, lameness scoring, Canine Brief Pain Inventory (CBPI), Pain Trace, and goniometry, and were done at baseline and 28, 56, and 84 days post-injection. Nine dogs completed the study. At day 84, 77.8% of dogs had a significant reduction in CBPI score and improvement in hip extension. All dogs demonstrated improved lameness and quality of life. These findings suggest that CEHM is a promising and low-risk intra-articular option for addressing canine hip OA.

Evaluating the Benefit and Tolerability of an Intra-Articular Injection of a Collagen-Elastin Hydrogel Microparticle (CEHM) Into the Stifle Joint of Dogs with Suspected Cruciate Ligament Rupture

Stewart SD, Thomson C, Kleeman E. 2023 ACVS Surgery Summit, Louisville, KY, October 12-14, 2023.

Cranial cruciate disease (CCD) is a common canine orthopedic condition. While surgery remains the gold standard treatment, intra-articular therapies offer a non-surgical option. This study evaluated the efficacy and safety of a collagen-elastin hydrogel microparticle (CEHM) injection, commercially known as Spryng, in dogs with suspected CCD. A Simon's two-stage design was employed to assess the response rate, defined as a 25% or greater reduction in the modified Glasgow Composite Pain Score (mGCPS) from baseline to day 28. Secondary endpoints included changes in visual lameness score (VLS) and Liverpool Osteoarthritis in Dogs (LOAD) survey scores. Results demonstrated a significant improvement in all clinical parameters, suggesting that CEHM may provide a viable non-surgical option for managing CCD in dogs.


Tolerability of Intra-Articular Administration of Spryng™ in Healthy Dogs

Reference: Clinical Study Assessing the Safety of Intra-Articular Administration of a Novel Micro-Particulate Biomaterial in the Management of Canine Osteoarthritis. Horter D, Kozlov S, Starek S. 
Study Report No. CA-202209, PetVivo, Inc. 2023

This study evaluated the tolerability of Spryng, a collagen-elastin hydrogel microparticulate (CEHM) biomaterial, when administered intra-articularly (IA) into multiple joints of healthy dogs. Twenty healthy beagle dogs received IA injections of Spryng or saline placebo into their stifle, elbow, shoulder, and hip joints in a randomized, blinded fashion. Lameness scoring, joint swelling scoring, and circumference measurements of the stifle and elbow joints were conducted on days 1, 7, and 14. Hematological and clinical chemistry parameters were monitored before and after each injection. Results demonstrated that Spryng injections were well-tolerated, with minimal to no adverse effects. There were no significant differences in joint swelling or pain between the Spryng and control groups. All monitored parameters remained within normal limits, indicating that Spryng is safe for IA administration in dogs.

Spryng Canine Poster Presentation 2023 ACVS Surgery Summit


Tolerability of Intra-Articular Administration of Spryng™ in Healthy Cats

Reference: Clinical Study Assessing the Safety of Intra-Articular Administration of a Novel Micro-Particulate Biomaterial in the Management of Feline Osteoarthritis. Horter D, Kozlov S, Starek S.
Study Report No. FE-202211, PetVivo, Inc. 2023

This study evaluated the safety and tolerability of Spryng, a collagen-elastin hydrogel microparticulate (CEHM) biomaterial, when administered intra-articularly (IA) into multiple joints of healthy cats. Ten healthy female cats received IA injections of Spryng into their shoulder, hip, elbow, and stifle joints, with control joints receiving phosphate-buffered saline. Clinical observations, lameness scoring, joint swelling assessments, were conducted prior to injection and on days 1, 7, and 14 after each round of injections. Hematology, clinical chemistry, and coagulation profiles were also monitored. Results demonstrated that Spryng injections were well-tolerated, with minimal to no adverse effects. There were no significant differences in joint swelling or pain between the Spryng and control groups. All monitored parameters remained within normal limits, indicating that Spryng is safe for IA administration in cats.



Tolerability of Intra-articular Administration of Spryng™ in the Hindlimb Joints of Horses


Hunyadi L, Sundman E. PetVivo, Inc., Study #PVE122021


Spryng™, an innovative collagen-elastin hydrogel microparticulate (CEHM) biomaterial, was evaluated for tolerability when injected intra-articularly (IA) in horses. This study aimed to assess the local and systemic effects of IA injection of Spryng into the tibiotarsal, medial femorotibial, and tarsometatarsal joints of horses. A masked, cohort safety study was conducted on 21 brood mares, with half of the joints receiving Spryng and the other half receiving saline. Horses were monitored for 14 days post-injection for signs of lameness, joint effusion, and heat. No statistically significant differences were observed between the Spryng and saline groups in terms of adverse events. While some horses experienced transient post-injection reactions, these were managed effectively with standard anti-inflammatory therapy with or without antibiotics. The results of this study suggest that Spryng is well-tolerated in horses and can be safely administered as an IA injection.


Colorado State University*

Principal investigator:
Felix Duerr, DVM, MS, Dr. med.vet., CCRT, DACVS-SA, DECVS, DACVSSMR

Study design:
Evaluation of intra-articular injection of a hydrophilic extracellular matrix biomaterial on naturally occurring elbow osteoarthritis-associated pain in dogs – a pilot study

Expected completion date:
Q2 2024